Spinal Muscular Atrophy Patient Recruitment in Vermont

TheraNovex connects clinical trial sponsors with pre-screened, eligible Spinal Muscular Atrophy patients across Vermont, including Burlington, South Burlington, Rutland, and beyond.

SMA patient recruitment for Type 1, 2, 3, and 4 studies including gene therapy and antisense oligonucleotide trials.

Who qualifies: Patients with SMA (SMN1 deletion/mutation confirmed) across all types, including treatment-naive and treated patients.

Recruitment challenges: SMN1/SMN2 copy number requirements and prior nusinersen/risdiplam eligibility criteria.

Our approach: Neuromuscular disease center networks, SMA patient advocacy partnerships, and genetic pre-screening.

Our recruitment network spans all major metropolitan areas in Vermont, ensuring broad geographic coverage for your Spinal Muscular Atrophy trial.